Related Experiment Video
Updated: May 6, 2026
A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
Published on: May 14, 2013
Early and mid-term results of drug-eluting stent implantation in unprotected left main
Alaide Chieffo1, Goran Stankovic, Erminio Bonizzoni
1San Raffaele Hospital, Milan, Italy.
Insights
Drug-eluting stents (DES) show improved safety and efficacy in unprotected left main coronary artery interventions compared to bare metal stents (BMS). This study suggests DES are a viable option for ULM treatment, warranting further investigation.
Area of Science:
- Interventional Cardiology
- Cardiovascular Medicine
- Medical Devices
Background:
- Percutaneous coronary intervention in unprotected left main (ULM) arteries remains a topic of debate regarding safety and efficacy.
- Assessing the outcomes of drug-eluting stents (DES) versus bare metal stents (BMS) in ULM interventions is crucial for clinical decision-making.
Purpose of the Study:
- To compare the safety and efficacy of drug-eluting stents (DES) versus bare metal stents (BMS) in patients undergoing elective percutaneous coronary intervention for unprotected left main coronary artery lesions.
Main Methods:
- Retrospective analysis of consecutive patients treated with sirolimus-eluting or paclitaxel-eluting stents (DES) for de novo unprotected left main lesions.
- Comparison of DES group (85 patients) with a historical control group treated with bare metal stents (BMS) (64 patients).
- Analysis included patient demographics, lesion characteristics, stent characteristics, and 6-month clinical follow-up for major adverse cardiac events.
Main Results:
- Patients treated with DES presented with higher-risk profiles, including lower ejection fractions, higher rates of diabetes, more distal left main involvement, smaller vessels, and longer stents.
- Despite the higher-risk patient and lesion characteristics, the incidence of major cardiac events at 6 months was significantly lower in the DES group (20.0%) compared to the BMS group (35.9%) (P=0.039).
- Cardiac deaths were numerically lower in the DES group (3.5%) compared to the BMS group (9.3%), although this did not reach statistical significance (P=0.17).
Conclusions:
- Early experience with drug-eluting stents in unprotected left main interventions demonstrates favorable and improved clinical outcomes compared to historical bare metal stent controls.
- The procedure appears safe, suggesting DES as a viable treatment option for unprotected left main disease.
- A randomized trial comparing DES with surgical revascularization is warranted to further validate these findings.
Background:
The safety and efficacy of percutaneous coronary intervention in unprotected left main (ULM) coronary arteries are still a matter of debate.
Methods And Results:
All consecutive patients who had a sirolimus-eluting stent (Cypher, Cordis, Johnson and Johnson Co) or a paclitaxel-eluting stent (Taxus, Boston Scientific) electively implanted in de novo lesions on unprotected left main were analyzed. Patients treated with a drug-eluting stent (DES) were compared with the historical group of consecutive patients treated with bare metal stent (BMS). Eighty-five patients were treated with DES; 64 had BMS implantation. Patients treated with DES had lower ejection fractions (51.1+/-11% versus 57.4+/-13%, P=0.002) and were more often diabetics (21.2% versus 10.9%, P=0.12) with more frequent distal left main involvement (81.2% versus 57.8%, P=0.003). Furthermore, in the DES group, smaller vessels (3.33+/-0.6 versus 3.7+/-0.7 mm, respectively; P=0.0001) with more lesions (2.94+/-1.6 versus 2.25+/-1.3, P=0.004) and vessels (2.03+/-0.69 versus 1.8+/-0.72, P=0.05) were treated with longer stents (24.3+/-12 versus 15.8+/-8.6 mm, P=0.0001). Despite the higher-risk patients and lesion profiles in the DES group, the incidence of major cardiac events at a 6-month clinical follow-up was lower in the DES than in the BMS group (20.0% versus 35.9%, respectively; P=0.039). Moreover, cardiac deaths occurred in 3 DES patients (3.5%), as compared with 6 (9.3%) in the BMS group (P=0.17).
Conclusions:
In this early experience with DES in unprotected left main, this procedure appears safe with favorable and improved clinical results as compared with historical control subjects with a BMS. A randomized study comparing surgery appears justified at present.
Related Concept Videos
01:14Prevention of Further Absorption of Poison
01:29Drug Delivery: Parenteral Route
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...